Tarsus Pharmaceuticals, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Acquisition or sale of assetsSep 10 →InsidersNo open-market buys. 9 insiders sold $14.8M, 22 of 45 sales on a 10b5-1 plan.→HoldersBlackRock 8.9%Deep Track Capital 8.5%RTW Investments 7.8%→Financing →PeersClosest companies: KOD, ALDX, SRPT→
From the filings
Figures
- Revenue
- $606.3Mlast 12 months
- Net income
- −$46.1Mlast 12 months
- Operating cash flow
- −$16.5Mlast 12 months
- Cash and equivalents
- $204.6Mat the last balance sheet
- Total debt
- $72.8Mat the last balance sheet
- Shares outstanding
- 43.3M shareson issue